Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Intervención contra la preeclampsia Países Bajos (PI-NL)

2 de noviembre de 2026 actualizado por: Dr Rebecca C. Painter, Amsterdam UMC

Metformina para la prolongación del embarazo en la preeclampsia pretérmino

The goal of this study is to find out if pregnant individuals with preterm preeclampsia (PE) who are treated with metformin can stay pregnant for longer, and if this is safe(r) for the mother and child. Preterm PE affects about 1 in 100 pregnant individuals in the Netherlands. Signs of preterm PE can be high blood pressure and protein in the urine in the second half of pregnancy (but before 32-34 weeks of pregnancy). Other symptoms can develop, such as problems with blood clotting and how well the blood cells, liver, lungs, and brain work. The disease can lead to serious complications for both the mother and child. The only way to cure preterm PE is to make sure the child is born, and many times, children have to be delivered (very) early (before 37 weeks). Children born (very) early can suffer from infections, breathing difficulties, and problems in their development.

Metformin is a medicine used to treat high blood sugar during and outside of pregnancy. In a previous study in South Africa, women with preterm PE that used metformin were able to safely remain pregnant for an extra week. Similarly, the main goal of the Preeclampsia Intervention NetherLands (PI-NL) study is to see if patients with preterm PE in the Netherlands that use metformin can remain pregnant for a longer time than patients taking a placebo. A placebo is a look-a-like capsule that contains no active ingredients. Researchers, the treating medical team, and participants will not know which participant gets which treatment. In addition, all participants will receive the standard care that all preterm PE patients get.

Descripción general del estudio

Estado

Reclutamiento

Condiciones

Intervención / Tratamiento

Descripción detallada

Preterm preeclampsia (PE) is a severe hypertensive disorder of pregnancy and a major cause of maternal and perinatal morbidity and mortality. Currently, the only treatment to halt disease progression is delivery of the dysfunctional placenta and thereby the child. This often happens prematurely. Being able to safely (for mother and child) extend pregnancy, even by a few days, is expected to reduce the short- and long-term risks associated with (severe) prematurity. Preclinical and recent clinical evidence presents metformin, a drug commonly used to treat diabetes in and outside of pregnancy, as a promising treatment candidate for preterm PE. Metformin might reduce inflammation, oxidative stress, and anti-angiogenesis, and improve endothelial function. In a recent South African trial, use of metformin was associated with a safe median 7.6 day prolongation of pregnancy in women with preterm PE, compared to placebo. There was a nonsignificant increase in the neonatal birthweight and a decrease in the length of stay in any neonatal nursery. Metformin did not lead to any serious adverse events.

The goal of this multicenter, triple-blind, randomized placebo-controlled trial is to investigate whether metformin can safely prolong gestation in patients with preterm PE in the Dutch population. Secondary outcomes include composite adverse maternal, fetal, and neonatal outcomes. Cost-effectiveness of the treatment will be evaluated.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

180

Fase

  • Fase 3

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Copia de seguridad de contactos de estudio

  • Nombre: R.C. Painter, Prof, MD, PhD
  • Número de teléfono: +31 20 566 9111
  • Correo electrónico: PI_NL@amsterdamumc.nl

Ubicaciones de estudio

      • Amsterdam, Países Bajos
        • Reclutamiento
        • Amsterdam UMC
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 50 años (Adulto)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Femenino

Descripción

Inclusion Criteria

All of the following:

  • Aged 18 years or older
  • Singleton pregnancy
  • Gestational age between 23+0 and 31+6 weeks
  • A diagnosis of preterm preeclampsia, defined according to modified International Society for the Study of Hypertension in Pregnancy (ISSHP) classification, including only those who have proteinuria (≥300 mg of protein in a 24-hour urine specimen or a protein-creatinine-ratio >50 in a single urine sample)
  • Estimated fetal weight >400 grams
  • No clear indication (maternal or fetal) or intention, by both the treating multidisciplinary team and the patient after counseling, to immediately deliver (or directly after corticosteroid administration) or to terminate the pregnancy otherwise.
  • Ability to understand English or Dutch
  • Ability and willingness to provide written informed consent

Exclusion Criteria

Any of the following:

  • Current use of metformin or a clinical indication for the use of metformin
  • A decision for immediate delivery (including cases where corticosteroids are administered with planned delivery directly after completion of treatment) or termination of pregnancy (e.g., due to disease severity in the patient combined with a dismal prognosis for the fetus), as made by the treating multidisciplinary team and the parent(s)
  • Contraindication(s) for the use of metformin (e.g., severe renal insufficiency, acute metabolic acidosis, severe liver insufficiency)
  • Use of drugs that might interact with metformin
  • Suspicion of a major fetal anomaly and/or chromosomal abnormality
  • Unable or unwilling to (completely) understand or provide informed consent, due to language, culture, or other barriers

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Cuadruplicar

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Metformin

Metformin 3000 mg divided by three daily doses (3 times 2 capsules of 500 mg; following a step-up schedule) from randomization till delivery, aside from usual preterm preeclampsia care.

Metformin Hydrochloride encapsulated immediate-release tablet of 500 mg, backfilled with cellulose.

Otros nombres:
  • Metformina
  • Clorhidrato de metformina
Comparador de placebos: Placebo

Placebo, divided by three daily doses (3 times 2 capsules; following a step-up schedule) from randomization till delivery, aside from usual preterm preeclampsia care.

Capsule filled with cellulose.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Number of days between randomization and delivery
Periodo de tiempo: Time between randomization and delivery (up to 37 weeks of gestation)

Prolongation of gestation

Time between randomization and delivery (up to 37 weeks of gestation)

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Number of participants reaching a composite maternal adverse outcome
Periodo de tiempo: Randomization till 90 days postpartum (unless otherwise specified)

Combined endpoint of maternal death (during pregnancy or within 42 days postpartum), eclampsia, pulmonary edema, severe renal impairment, cerebrovascular accident, placental abruption, and/or liver hematoma or rupture.

Randomization till 90 days postpartum (unless otherwise specified)
Number of participants reaching a composite fetal adverse outcome
Periodo de tiempo: Randomization till delivery (up to 37 weeks of gestation)

Combined endpoint of intrauterine fetal demise, suboptimal fetal condition based on CTG, and fetal growth restriction.

Randomization till delivery (up to 37 weeks of gestation)
Number of participants reaching a composite neonatal adverse outcome
Periodo de tiempo: Birth till 90 days after birth (unless otherwise specified)

Combined endpoint of neonatal death (within 28 days after birth), grade 3 or 4 intraventricular hemorrhage, retinopathy of prematurity requiring treatment, necrotizing enterocolitis (grade II or higher), bronchopulmonary dysplasia, neonatal sepsis, and cystic periventricular leukomalacia (grade II or higher)

Birth till 90 days after birth (unless otherwise specified)

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
Maternal individual exploratory outcomes
Periodo de tiempo: Randomization till 90 days postpartum (unless otherwise specified)

Number of participants experiencing each of the following: maternal death, cerebrovascular event, eclampsia, cortical blindness, pulmonary edema, AKI, liver hematoma/rupture, placental abruption, retinal detachment, postpartum hemorrhage, HELLP syndrome, severe elevated liver enzymes, low platelets, left ventricular heart failure, PRES, DIC, thromboembolic disease, need for dialysis due to renal failure, admission to high or ICU, need for intubation and mechanical ventilation

Randomization till 90 days postpartum (unless otherwise specified)
Fetal individual exploratory outcomes
Periodo de tiempo: Randomization till 90 days postpartum (unless otherwise specified)

Number of participants experiencing each of the following: intrauterine or intrapartum fetal death, reversed end diastolic flow in umbilical artery on at least 2 occasions, redistribution in the middle cerebral artery, absent or reversed a-wave in ductus venosus, suboptimal fetal condition based on CTG.

Randomization till 90 days postpartum (unless otherwise specified)
Neonatal individual exploratory outcomes
Periodo de tiempo: Randomization till 90 days postpartum (unless otherwise specified)

Number of participants experiencing each of the following: neonatal death within 28 days after birth, neonatal death between 29 and 90 days after birth, growth restriction at birth, Apgar score < 7 at 5 min, umbilical artery pH < 7.10, neonatal hypoglycemia, neonatal seizures, intraventricular hemorrhage, necrotizing enterocolitis, retinopathy of the premature, pulmonary insufficiency of the preterm infant, bronchopulmonary dysplasia, cystic periventricular leukomalacia, patent ductus arteriosus, persistent pulmonary hypertension, surfactant use within 72 hours after birth, need for respiratory support, admission to NICU.

Randomization till 90 days postpartum (unless otherwise specified)
Mean neonatal birthweight
Periodo de tiempo: Within the first 24 hours after birth

In grams

Within the first 24 hours after birth
Median neonatal length of stay in any neonatal nursery, including NICU
Periodo de tiempo: Birth till 90 days postpartum

In days

Birth till 90 days postpartum
Incremental cost-effectiveness ratios (ICERs; exploratory)
Periodo de tiempo: Start of pregnancy till 90 days postpartum

Determined through length of maternal stay in hospital (and specifically ICU), neonatal length of stay in hospital (and specifically NICU), other health care utilization (based on iMCQ questionnaire, maternal and neonatal use of medication during pregnancy and after birth), loss of productivity (measured with iPCQ questionnaire), quality-of-life (score on EQ-5D-5L).

Start of pregnancy till 90 days postpartum
Rate of diarrhea, nausea/vomiting, abdominal pain, headache (all based on PHASE-20 questionnaire), lactic acidosis, and hypoglycemia (individually)
Periodo de tiempo: Randomization till delivery (up to 37 weeks of gestation)

Tolerability and safety of metformin

Randomization till delivery (up to 37 weeks of gestation)
Score on PROMIS Anxiety 8a Short Form
Periodo de tiempo: Randomization till 90 days postpartum

Maternal anxiety

Randomization till 90 days postpartum
Score on EPDS
Periodo de tiempo: Randomization till 90 days postpartum

Maternal depressive symptoms

Randomization till 90 days postpartum
Score on Rosenberg Self-Esteem Scale
Periodo de tiempo: Randomization till 90 days postpartum

Maternal self-esteem

Randomization till 90 days postpartum
Score on City Birth Trauma Scale
Periodo de tiempo: Randomization till 90 days postpartum

Childbirth-related PTSD

Randomization till 90 days postpartum

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Colaboradores

Investigadores

  • Investigador principal: R.C. Painter, Prof, MD, PhD, Amsterdam UMC

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

19 de septiembre de 2025

Finalización primaria (Estimado)

19 de marzo de 2029

Finalización del estudio (Estimado)

19 de junio de 2029

Fechas de registro del estudio

Enviado por primera vez

31 de mayo de 2024

Primero enviado que cumplió con los criterios de control de calidad

5 de junio de 2024

Publicado por primera vez (Actual)

11 de junio de 2024

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

4 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

2 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • PI-NL trial
  • 2023-510382-10-00 (Ctis)
  • 2023 (Subvención/contrato del NIH de EE. UU.)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

The investigators plan to collaborate with researchers of the international Preeclampsia Intervention (PI) trials.

Marco de tiempo para compartir IPD

T.b.d.

Criterios de acceso compartido de IPD

The results of the IPD will be published in a peer-reviewed journal.

Tipo de información de apoyo para compartir IPD

  • PROTOCOLO DE ESTUDIO
  • SAVIA
  • CÓDIGO_ANALÍTICO
  • RSC

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

producto fabricado y exportado desde los EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .